Free beta — full access, free until October 2026. No card, no auto-charge — paid plans are opt-in when they launch.
Company
Evotec SE (EVO)
Standardized SEC financial data for Evotec SE — income statement, balance sheet, cash flow and 40+ ratios, available as a clean JSON API. CIK 0001412558 · NASDAQ · Pharmaceutical Preparations.
Gross margin
14.4%
Net margin
-24.6%
Revenue growth (YoY)
2.0%
Return on equity
-20.6%
Ratios for fiscal year 2024, standardized from SEC filings.
Income statement
€
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
Revenue
€446.4M
€500.9M
€618.0M
€751.4M
€781.4M
€797.0M
Cost of revenue
€313.5M
€375.2M
€466.5M
€577.4M
€606.4M
€682.1M
Gross profit
€132.9M
€125.7M
€151.5M
€174.1M
€175.1M
€114.9M
R&D expense
€58.4M
€63.9M
Standardized from Evotec SE's SEC filings — per-share figures split-adjusted. Full history via the API.